The enhanced capacity of ΔmmaA4BCG/adjuvant and BCG/adjuvant vaccine formulations to induce elevated concentrations of the TNFα/IL-2 producing central memory T cells may contribute to the increased anti-tuberculosis protection seen after immunization with these preparations. This evidence concerns the gene TNF and tuberculosis.